1. AHRO : Austin Health Research Online

Jonathan S Cebon

View Statistics Email Alert RSS Feed
 Claim profile

Profile

Loading... 2 0 20 0 false
Credit Name
Jonathan S Cebon
Full Name
Cebon, Jonathan S
 
Department
 
ORCID
Loading... 3 0 20 0 false

Publications

Refined By:
Author:  Cebon, Jonathan S

Results 101-120 of 150 (Search time: 0.014 seconds).

Publication YearTitleAuthor(s)
1011-Jun-2011Melanoma vaccines: developments over the past 10 years.Klein, Oliver ; Schmidt, Christopher; Knights, Ashley J; Davis, Ian D; Chen, Weisan; Cebon, Jonathan S 
1024-Nov-2010Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.Svobodová, Suzanne; Browning, Judy; MacGregor, Duncan; Pollara, Gabriele; Scolyer, Richard A; Murali, Rajmohan; Thompson, John F; Deb, Siddhartha; Azad, Arun A; Davis, Ian D; Cebon, Jonathan S 
10318-Oct-2010Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.Wei, Joe; Waithman, Jason; Lata, Roleen; Mifsud, Nicole A; Cebon, Jonathan S ; Kay, Thomas; Smyth, Mark J; Sadler, Anthony J; Chen, Weisan
1041-Jun-2010Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.Cebon, Jonathan S ; Knights, Ashley J; Ebert, Lisa; Jackson, Heather M; Chen, Weisan
10529-Apr-2010Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.Robson, Neil C; McAlpine, Tristan; Knights, Ashley J; Schnurr, Max; Shin, Amanda; Chen, Weisan; Maraskovsky, Eugene; Cebon, Jonathan S 
1061-Mar-2010Cancer vaccines: Where are we going?Cebon, Jonathan S 
1077-Nov-2009Cancer stem cells in urologic cancers.Gedye, Craig; Davidson, Adee-Jonathan; Elmes, Martin R; Cebon, Jonathan S ; Bolton, Damien M ; Davis, Ian D
10810-Mar-2009Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.Davis, Ian D; Brady, Ben; Kefford, Richard F; Millward, Michael; Cebon, Jonathan S ; Skrumsager, Birte K; Mouritzen, Ulrik; Hansen, Lasse Tengbjerg; Skak, Kresten; Lundsgaard, Dorthe; Frederiksen, Klaus Stensgaard; Kristjansen, Paul E G; McArthur, Grant A
10910-Mar-2009Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.Nicholaou, Theo; Ebert, Lisa M; Davis, Ian D; McArthur, Grant A; Jackson, Heather M; Dimopoulos, Nektaria; Tan, Bee; Maraskovsky, Eugene; Miloradovic, Lena; Hopkins, Wendie; Pan, Linda; Venhaus, Ralph; Hoffman, Eric W; Chen, Weisan; Cebon, Jonathan S 
11017-Feb-2009Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.Gedye, Craig; Quirk, Juliet; Browning, Judy; Svobodová, Suzanne; John, Thomas ; Sluka, Pavel; Dunbar, P Rod; Corbeil, Denis; Cebon, Jonathan S ; Davis, Ian D
11127-Jan-2009A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.Ebert, Lisa M; Liu, Yu Chih; Clements, Craig S; Robson, Neil C; Jackson, Heather M; Markby, Jessica L; Dimopoulos, Nektaria; Tan, Bee Shin; Luescher, Immanuel F; Davis, Ian D; Rossjohn, Jamie; Cebon, Jonathan S ; Purcell, Anthony W; Chen, Weisan
11213-Jan-2009Activin-A attenuates several human natural killer cell functions.Robson, Neil C; Wei, Heng; McAlpine, Tristan; Kirkpatrick, Naomi; Cebon, Jonathan S ; Maraskovsky, Eugene
11315-Aug-2008Predicting clinical outcome through molecular profiling in stage III melanoma.John, Thomas ; Black, Michael A; Toro, Tumi T; Leader, Debbie; Gedye, Craig A; Davis, Ian D; Guilford, Parry J; Cebon, Jonathan S 
11415-Apr-2008The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.Ebert, Lisa M; Tan, Bee Shin; Browning, Judy; Svobodova, Suzanne; Russell, Sarah E; Kirkpatrick, Naomi; Gedye, Craig; Moss, Denis; Ng, Sweet Ping ; MacGregor, Duncan; Davis, Ian D; Cebon, Jonathan S ; Chen, Weisan
1151-Dec-2007Immunotherapy of advanced or metastatic melanoma.Cebon, Jonathan S ; Gedye, Craig; John, Thomas ; Davis, Ian D
11615-Jun-2007An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.Davis, Ian D; Skrumsager, Birte K; Cebon, Jonathan S ; Nicholaou, Theo; Barlow, John W; Moller, Niels Peter Hundahl; Skak, Kresten; Lundsgaard, Dorthe; Frederiksen, Klaus Stensgaard; Thygesen, Peter; McArthur, Grant A
11710-Sep-2006Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.Davis, Ian D; Chen, Qiyuan; Morris, Leone; Quirk, Juliet; Stanley, Maureen; Tavarnesi, Maria L; Parente, Phillip; Cavicchiolo, Tina; Hopkins, Wendie; Jackson, Heather M; Dimopoulos, Nektaria; Tai, Tsin Yee; MacGregor, Duncan; Browning, Judy; Svobodova, Suzanne; Caron, Dania; Maraskovsky, Eugene; Old, Lloyd J; Chen, Weisan; Cebon, Jonathan S 
1181-Aug-2006Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.Lim, Elgene; Browning, Judy; MacGregor, Duncan; Davis, Ian D; Cebon, Jonathan S 
1191-Jun-2006Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Nicholaou, Theo; Ebert, Lisa; Davis, Ian D; Robson, Neil; Klein, Oliver ; Maraskovsky, Eugene; Chen, Weisan; Cebon, Jonathan S 
12015-May-2006Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.Jackson, Heather M; Dimopoulos, Nektaria; Mifsud, Nicole A; Tai, Tsin Yee; Chen, Qiyuan; Svobodova, Suzanne; Browning, Judy; Luescher, Immanuel F; Stockert, Lisa; Old, Lloyd J; Davis, Ian D; Cebon, Jonathan S ; Chen, Weisan